Millipore Sigma Vibrant Logo

IM29L Anti-PAI-1 (Ab-1) Mouse mAb (2)

This Anti-PAI-1 (Ab-1) Mouse mAb (2) is validated for use in Immunoblotting, Immunoprecipitation, Immunocytochemistry for the detection of PAI-1 (Ab-1).

Anti-PAI-1 (Ab-1) Mouse mAb (2) MSDS (material safety data sheet) or SDS, CoA and CoQ, dossiers, brochures and other available documents.

Synonyms: Anti-Plasminogen Activator Inhibitor-1

View Products on Sigmaaldrich.com
IM29L
View Pricing & Availability

Overview

Replacement Information

Key Specifications Table

Species ReactivityHostAntibody Type
HMMonoclonal Antibody

Pricing & Availability

Catalog Number AvailabilityPackaging Qty/Pack Price Quantity
IM29L-100UG
Retrieving availability...
—
Limited AvailabilityLimited Availability
Stocked 
Discontinued
Limited Quantities Available
Available
    Remaining : Will advise
      Remaining : Will advise
      Will advise
      Contact Customer Service
      Contact Customer Service

      		 Plastic ampoule 100 μg
      Retrieving price...
      Price could not be retrieved
      Minimum Quantity is a multiple of
      Maximum Quantity is
      Upon Order Completion More Information
      You Saved ()
       
      —
      Request Pricing
      		 —
      Description
      OverviewRecognizes both active and latent forms of the ~50 kDa PAI-1 protein in conditioned media from dexamethasone-treated HT-1080 cells. Sold under license of U.S. Patent 5,422,245.
      Catalogue NumberIM29L
      Brand Family Calbiochem®
      SynonymsAnti-Plasminogen Activator Inhibitor-1
      References
      ReferencesJanicke, F., et al. 1994. Cancer Research. 54, 2527.
      Lawrence, D. A., et al. 1994. J. Biol. Chem. 269, 15223.
      Nagayama, M., et al. 1994. Cancer 73, 1398.
      Petersen, H., et al. 1994. Cancer Res. 54, 120.
      Keijer, J., et al. 1991. Blood 78, 401.
      Blasi, F. and Verde, P., 1990. in Seminars in Cancer Biol. Vol. 1, 153.
      Declerck, P. J. and Collen, D., 1990. Thrombosis Res. Supplement X 3.
      Nielsen, L. S., et al. 1986. Thrombosis and Haemostasis. 55, 206.
      Product Information
      DeclarationSold under license of U.S. Patent 5,422,245.
      FormLyophilized
      FormulationLyophilized from a volatile buffer, 100 µg BSA.
      Positive controlConditioned media from dexamethasone-treated (1 µM) HT-1080 cells
      PreservativeNone
      Quality LevelMQ100
      Applications
      Application ReferencesImmunoprecipitation Keijer, J., et al. 1991. Blood 78, 401 Original Clone, Immunocytochemistry, Neutralization Studies Nielsen, L. S., et al. 1986. Thrombosis and Haemostasis. 55, 206.
      Key Applications Neutralization Studies
      Immunoblotting (Western Blotting)
      Immunocytochemistry
      Immunoprecipitation
      Application NotesImmunoblotting (1 µg/ml)
      Immunoprecipitation (see application references)
      Immunocytochemistry (see application references
      Neutralization Studies (see application references)
      Application CommentsAntibody should be titrated for optimal results in individual systems.
      Biological Information
      Immunogenpartially purified PAI-1 from conditioned medium of dexamethasone-treated HT1080 human cells
      ImmunogenHuman
      Clone2
      HostMouse
      IsotypeIgG₁
      Species Reactivity
      • Human
      Antibody TypeMonoclonal Antibody
      Physicochemical Information
      Dimensions
      Materials Information
      Toxicological Information
      Safety Information according to GHS
      Safety Information
      Product Usage Statements
      Storage and Shipping Information
      Ship Code Ambient Temperature Only
      Toxicity Standard Handling
      Storage +2°C to +8°C
      Do not freeze Ok to freeze
      Special InstructionsWe recommend resuspending the lyophilized antibody with sterile phosphate buffered saline (PBS), pH 7.4, or sterile 20 mM Tris-saline (20 mM Tris containing 0.15 M NaCl), pH 7.4, to yield a final concentration of 100 µg/ml. Lyophilized antibodies should be resuspended at 4°C with occasional gentle mixing for at least 2 h.
      Packaging Information
      Transport Information
      Supplemental Information
      Specifications

      Documentation

      Anti-PAI-1 (Ab-1) Mouse mAb (2) SDS

      Title

      Safety Data Sheet (SDS) 

      Anti-PAI-1 (Ab-1) Mouse mAb (2) Certificates of Analysis

      TitleLot Number
      IM29L

      References

      Reference overview
      Janicke, F., et al. 1994. Cancer Research. 54, 2527.
      Lawrence, D. A., et al. 1994. J. Biol. Chem. 269, 15223.
      Nagayama, M., et al. 1994. Cancer 73, 1398.
      Petersen, H., et al. 1994. Cancer Res. 54, 120.
      Keijer, J., et al. 1991. Blood 78, 401.
      Blasi, F. and Verde, P., 1990. in Seminars in Cancer Biol. Vol. 1, 153.
      Declerck, P. J. and Collen, D., 1990. Thrombosis Res. Supplement X 3.
      Nielsen, L. S., et al. 1986. Thrombosis and Haemostasis. 55, 206.
      Data Sheet

      Note that this data sheet is not lot-specific and is representative of the current specifications for this product. Please consult the vial label and the certificate of analysis for information on specific lots. Also note that shipping conditions may differ from storage conditions.

      Revision28-September-2007 JSW
      SynonymsAnti-Plasminogen Activator Inhibitor-1
      ApplicationImmunoblotting (1 µg/ml)
      Immunoprecipitation (see application references)
      Immunocytochemistry (see application references
      Neutralization Studies (see application references)
      DescriptionPurified mouse monoclonal antibody (see application references). Recognizes both active and latent forms of the ~50 kDa PAI-1 protein.
      BackgroundPlasminogen activator inhibitor 1 (PAI-1) is a secreted glycoprotein of approximately 50 kDa, which functions as the primary regulator of uPA and tPA activity. PAI-1 and the related inhibitor, PAI-2, are members of the serine proteinase inhibitor (serpin) gene superfamily. PAI-1 is produced by a variety of cell types and is present in normal human plasma. It exists as two conformationally distinct forms, latent and active. The active form binds to uPA in a 1:1 complex resulting in the inhibition of proteolytic activity. Active PAI-1 rapidly converts to the latent form but can be stabilized in the active conformation by binding to the cell adhesion glycoprotein, vitronectin. Latent PAI-1 can be activated in vitro by exposure to denaturants such as SDS or guanidine. PAI-1 levels are increased in a number of disease states including coronary artery disease, venous thrombosis, obesity and various types of cancer. Recent studies indicate that elevated PAI-1 may be a useful prognostic marker for several types of cancers, particularly breast and lung.
      HostMouse
      Immunogen speciesHuman
      Immunogenpartially purified PAI-1 from conditioned medium of dexamethasone-treated HT1080 human cells
      Clone2
      IsotypeIgG₁
      Specieshuman
      Positive controlConditioned media from dexamethasone-treated (1 µM) HT-1080 cells
      FormLyophilized
      FormulationLyophilized from a volatile buffer, 100 µg BSA.
      PreservativeNone
      CommentsAntibody should be titrated for optimal results in individual systems.
      Storage +2°C to +8°C
      Do Not Freeze Ok to freeze
      Special InstructionsWe recommend resuspending the lyophilized antibody with sterile phosphate buffered saline (PBS), pH 7.4, or sterile 20 mM Tris-saline (20 mM Tris containing 0.15 M NaCl), pH 7.4, to yield a final concentration of 100 µg/ml. Lyophilized antibodies should be resuspended at 4°C with occasional gentle mixing for at least 2 h.
      Toxicity Standard Handling
      ReferencesJanicke, F., et al. 1994. Cancer Research. 54, 2527.
      Lawrence, D. A., et al. 1994. J. Biol. Chem. 269, 15223.
      Nagayama, M., et al. 1994. Cancer 73, 1398.
      Petersen, H., et al. 1994. Cancer Res. 54, 120.
      Keijer, J., et al. 1991. Blood 78, 401.
      Blasi, F. and Verde, P., 1990. in Seminars in Cancer Biol. Vol. 1, 153.
      Declerck, P. J. and Collen, D., 1990. Thrombosis Res. Supplement X 3.
      Nielsen, L. S., et al. 1986. Thrombosis and Haemostasis. 55, 206.
      Application referencesImmunoprecipitation Keijer, J., et al. 1991. Blood 78, 401 Original Clone, Immunocytochemistry, Neutralization Studies Nielsen, L. S., et al. 1986. Thrombosis and Haemostasis. 55, 206.